CLAIMS

1. The use of an antibody or a fragment thereof that binds to a ganglioside GM2 in the manufacture of a therapeutic or diagnostic agent for the treatment of mesothelioma.

2. The use according to claim 1, wherein the mesothelioma is one selected from pleural mesothelioma, peritoneal mesothelioma and pericardial mesothelioma.

3. The use according to claim 2, wherein the pleural mesothelioma or the peritoneal mesothelioma is malignant pleural mesothelioma or malignant peritoneal mesothelioma.

4. The use according to any one of claims 1 to 3, wherein the antibody is an antibody that binds to the α2-3 linked sialic acid (SA) of GM2.

5. The use according to any one of claims 1 to 4, wherein the antibody is a monoclonal antibody.

6. The use according to any one of claims 1 to 5, wherein the antibody is a recombinant antibody.

7. The use according to claim 6, wherein the recombinant antibody is one selected from a chimeric antibody, a humanized antibody, and a human antibody.

8. The use according to any one of claims 1 to 7, wherein the antibody is an antibody that comprises heavy chain (hereinafter, "H chain") complementarity determining regions (CDRs; hereinafter, abbreviated to "CDRs") 1 to 3 having the amino acid sequences of SEQ ID NOS: 1 to 3, respectively, and light chain (hereinafter, "L chain") CDRs 1 to 3 having the amino acid sequences of SEQ ID NOS: 4 to 6, respectively.

9. The use according to any one of claims 1 to 8, wherein the antibody is one selected from:

an antibody that comprises an H-chain variable region (hereinafter, referred to as "VH") having the amino acid sequence of SEQ ID NO: 7 and an L-chain variable region (hereinafter, referred to as "VL") having the amino acid sequence of SEQ ID NO: 8;

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 7 and a VL having the amino acid sequence of SEQ ID NO: 9;

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 10 and a VL having the amino acid sequence of SEQ ID NO: 8; and

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 10 and a VL having the amino acid sequence of SEQ ID NO: 11.

9. The use according to any one of claims 1 to 8, comprising at least one concomitant drug.

10. The use according to claim 9, wherein the concomitant drug is at least one selected from a chemotherapeutic agent and a protein drug.

CLAIMS

1. The use of an antibody or a fragment thereof that binds to a ganglioside GM2 in the manufacture of a therapeutic or diagnostic agent for the treatment of mesothelioma, wherein the antibody is an antibody that comprises heavy chain (hereinafter, "H chain") complementarity determining regions (CDRs; hereinafter, abbreviated to "CDRs") 1 to 3 having the amino acid sequences of SEQ ID NOS: 1 to 3, respectively, and light chain (hereinafter, "L chain") CDRs 1 to 3 having the amino acid sequences of SEQ ID NOS: 4 to 6, respectively.

2. The use according to claim 1, wherein the mesothelioma is one selected from pleural mesothelioma, peritoneal mesothelioma and pericardial mesothelioma.

3. The use according to claim 2, wherein the pleural mesothelioma or the peritoneal mesothelioma is malignant pleural mesothelioma or malignant peritoneal mesothelioma.

4. The use according to any one of claims 1 to 3, wherein the antibody is an antibody that binds to the α2-3 linked sialic acid (SA) of GM2.

5. The use according to any one of claims 1 to 4, wherein the antibody is a monoclonal antibody.

6. The use according to any one of claims 1 to 5, wherein the antibody is a recombinant antibody.

7. The use according to claim 6, wherein the recombinant antibody is one selected from a chimeric antibody, a humanized antibody, and a human antibody.

8. The use according to any one of claims 1 to 7, wherein the antibody is one selected from:

an antibody that comprises an H-chain variable region (hereinafter, referred to as "VH") having the amino acid sequence of SEQ ID NO: 7 and an L-chain variable region (hereinafter, referred to as "VL") having the amino acid sequence of SEQ ID NO: 8;

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 7 and a VL having the amino acid sequence of SEQ ID NO: 9;

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 10 and a VL having the amino acid sequence of SEQ ID NO: 8; and

an antibody that comprises a VH having the amino acid sequence of SEQ ID NO: 10 and a VL having the amino acid sequence of SEQ ID NO: 11.

9. The use according to any one of claims 1 to 8, comprising at least one concomitant drug.

10. The use according to claim 9, wherein the concomitant drug is at least one selected from a chemotherapeutic agent and a protein drug.